https://www.selleckchem.com/pr....oducts/Cediranib.htm
Patients with T790M detected at treatment initiation (±3 months) had significantly shorter PFS than patients where T790M was first detected 3 months post treatment initiation (median PFS 5.9 vs. 26.5 months; p less then 0.0001). However, time from T790M detection to disease progression was not significantly different between the two groups (median around 5 months). In conclusion, Sel-Cap is a highly sensitive platform for EGFR mutations in plasma, and the timing of the first appearance of T790M in plasma, determined via highly sen
Like
Comment
Share
